CMC Biologics, Inc. and Zymeworks Inc. have entered into a Master Services Agreement for the process development, formulation development, and cGMP clinical manufacture of a recombinant human IgG1 bi-specific (heterodimeric) antibody.   “Being selected by Zymeworks, who are known for developing best-in-class and highly effective protein therapeutics, is a natural fit for us and validates our technical excellence and partnering philosophy,” said Gustavo Mahler, Ph.D., global chief ope...